Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick
Tag: Clinical trial
Results of HPBCD-enabled MTX110 Phase I Study
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, announced encouraging headline results
Final Results of NIAID’s Trial Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19
— Final Day 29 Data Show Superior Efficacy of Veklury Compared with Placebo in Hospitalized Patients Receiving Standard of Care
Ivermectin against COVID-19
Ivermectin is a medication used to treat a number of parasite infections. Chemically, this compound and derivatives are macrocyclic lactones
Novel dexamethasone formulation shows efficacy and safety with once-daily use
Eric D. Donnenfeld, a consultant to Oculis reported for Ophthalmology Times on the results of a phase 2 trial: dexamethasone
Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Oculis Successful End-Of-Phase 2 Meeting With The FDA, On Towards Phase 3
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently announced that they are progressing towards Phase 3 with OCS-01 in two
Clinical trial: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses
Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of
Inhaled Interferons to treat COVID-19
Why interferons? SARS CoV viruses block interferon production in infected cells, allowing the virus to continue replicating unabated. Treatment with interferons
Gilead to Test a Version of Remdesivir That Can Be Inhaled
The New York Times published on June 22, 2020: The American biopharmaceutical company Gilead Sciences will soon start trials of